EN DE
STOCK COMPARISON

Excelsior Biopharma vs Merck & Company: Fair Value & Quality

Both stocks run through our valuation models. Here is how Excelsior Biopharma (6496) and Merck & Company (MRK) compare, as of Aug 26, 2026.

As of Aug 26, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Excelsior Biopharma trades at TWD 24.90 versus a fair value of TWD 7.90 (-68%), while Merck & Company trades at $156 versus $125 (-20%).
Excelsior Biopharma
6496.TWO · TWD · Health Care
-68%
upside to fair value
overvalued
PriceTWD 24.90
Fair ValueTWD 7.90
Quality43/100
Merck & Company
MRK · USD · Health Care
-20%
upside to fair value
overvalued
Price$156
Fair Value$125
Quality70/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Excelsior BiopharmaMerck & Company
Valuation
P/E (TTM)45.3×
0.04×P/S (TTM)4.64×
0.05×P/B5.80×
EV/EBITDA11.4×
PEG6.10×
4.1%Dividend yield2.1%
Dividend per share$3.28
Profitability
-22%Net margin14%
-25%Operating margin39%
-23%Return on equity19%
-8%Return on assets13%
Growth
4%Revenue growth (YoY)5%
10.2%Avg. growth/yr (3Y)3.1%
-9.1%Avg. growth/yr (5Y)9.4%
Balance & size
0.14×Debt / equity0.89×
$37MMarket cap$305B
weakGrowth qualityhealthy

Merck & Company leads: 5 to 6 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Excelsior Biopharmaof which business quality 42 · market factors 51 Merck & Companyof which business quality 68 · market factors 90
ProfitabilityMargins and returns on capital today
17
74
Quality GrowthAre margins and returns improving?
27
36
CashflowEarnings quality: real cash, not paper profit
6
65
Fin. StrengthBalance sheet, leverage, solvency risk
56
68
InvestmentDisciplined investing over empire-building
96
71
Low VolatilityCalm price path (market factor)
90
84
MomentumPrice trend over the last 3–12 months (market factor)
37
87
52W MomentumDistance to the 52-week high (market factor)
30
100
Net IssuanceBuybacks instead of dilution
87
91

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Excelsior Biopharma

Dividend DiscountTWD 8.85
Asset-BasedTWD 11.59

3 of 3 models see the stock below the current price.

Merck & Company

DCF Models$117
Earnings-Based$62.77
Dividend Discount$60.35
Multiples$122
Asset-Based$14.27
Growth DCF$74.00
Economic Profit$83.85
Growth Earnings$138

25 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Excelsior Biopharma
Bear TWD 7.36Fair Value TWD 7.90Bull TWD 8.69
TWD 24.90 = current price (white tick)
Merck & Company
Bear $70.92Fair Value $125Bull $188
$156 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Excelsior Biopharma · Health Care

Quality score43 · below median
Fair value upside-68% · bottom 25%

Merck & Company · Health Care

Quality score70 · Top 25%
Fair value upside-20% · above median

Bottom line

As of Aug 26, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Excelsior Biopharma trades at TWD 24.90 versus a fair value of TWD 7.90 (-68%), while Merck & Company trades at $156 versus $125 (-20%).

Merck & Company has the higher quality score (70/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.